Clinical trials: Attention Deficit Disorder (ADD)
ADHD
KP415 Classroom Study in Children (6-12 Years of Age) With ADHD
The study is a multicenter, dose-optimized, double-blind, randomized, placebo-controlled, parallel efficacy laboratory classroom study with KP415 in children with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT03292952
- Testing
- KP415 oral capsule
- Where
- 5 sites in United States
- Volunteers
- 155 people
- Sponsor
- Zevra Therapeutics
ADHD
Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to assess the effect on driving performance of a single dose of amphetamine extended-release tablets (20 mg/tablet) compared with placebo at 45 minutes and 10 hours post-dose in young adults with ADHD.
- Trial name
- NCT04027361
- Testing
- Amphetamine Extended Release (ER) Tablet 20 mg
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Tris Pharma, Inc.
ADHD - Attention Deficit Disorder With Hyperactivity
Brain Stimulation and Attention Control in Children With ADHD
The goal of this clinical trial is to learn if brain stimulation can help children ages 6 to 12 with attention-deficit/hyperactivity disorder (ADHD) improve their attention and self-control.
- Trial name
- NCT07182344
- Testing
- Intermittent Theta Burst Stimulation to Right DLPFC
- Where
- 2 sites in Kazakhstan
- Volunteers
- 40 people
- Sponsor
- Neurolab Plus
ADHD, Narcolepsy
Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR)
This is a randomized, double-blind, double-dummy, placebo- and active-controlled 4 period, 4 way crossover study to assess the intranasal abuse potential of manipulated ADAIR formulation in nondependent, recreational stimulant…
- Trial name
- SEAL (NCT04647903)
- Testing
- ADAIR 10 mg IR tablets, d-amphetamine sulfate
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Vallon Pharmaceuticals, Inc.
Attention-Deficit/Hyperactivity Disorder
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.
- Trial name
- NCT04781140
- Testing
- 100mg SPN-812
- Where
- 54 sites in United States
- Volunteers
- 286 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder
Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD
The purpose of this study is to evaluate the safety and efficacy of ORADUR®-Methylphenidate in children and adolescents with ADHD.
- Trial name
- NCT02450890
- Where
- 4 sites in Taiwan
- Volunteers
- 114 people
- Sponsor
- Orient Pharma Co., Ltd.
Disruptive Behavior Disorder
A Study of the Safety of Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior Disorders
The primary purpose of this study is to document the long-term safety of an oral formulation of risperidone in the treatment of children and adolescents with conduct and other disruptive behavior disorders.
- Trial name
- NCT00236470
- Testing
- risperidone
- Volunteers
- 232 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Attention Deficit Disorder With Hyperactivity
Effectiveness of Lobeline in Treating Symptoms of ADHD in Adult Patients
The study will evaluate the effectiveness of the nonstimulant medication lobeline in improving symptoms of attention deficit hyperactivity disorder in adults.
- Trial name
- NCT00664703
- Testing
- Lobeline sulfate, Methylphenidate HCl
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Yaupon Therapeutics
ADHD - Attention Deficit Disorder With Hyperactivity, ADHD - Combined Type
Multi-center, Single Blinded, RCT, Pivotal Study to Evaluate the Efficacy and Safety of DTx to Improve ADHD
Background: Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by inattention, hyperactivity, impulsivity, and impaired executive functioning.
- Conditions
- ADHD - Attention Deficit Disorder With Hyperactivity, ADHD - Combined Type, ADHD
- Trial name
- NCT07173439
- Testing
- Model Name: EMT-SR01;red
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- EMOTIV
Attention-Deficit/Hyperactivity Disorder
Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to investigate the treatment effectiveness of Adhansia XR at month-2 after initiation, and the effectiveness of Adhansia XR overall and when compared with the active comparator group (Concerta) over…
- Trial name
- RE-DAX (NCT04507204)
- Testing
- Adhansia XR, Concerta
- Where
- 35 sites in United States
- Volunteers
- 267 people
- Sponsor
- Purdue Pharma LP
Attention Deficit Disorder With Hyperactivity
Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar
Determine if there is a difference in treatment response for adults with ADHD who are treated with Strattera versus those treated with a combination of Strattera and buspirone
- Trial name
- NCT00174226
- Testing
- Atomoxetine, Buspirone
- Where
- 11 sites in United States
- Volunteers
- 241 people
- Sponsor
- Pfizer
Attention Deficit Disorder With Hyperactivity
TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to determine whether TRI102 is effective in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children ages 6-12.
- Trial name
- NCT02083783
- Testing
- TRI102
- Where
- 5 sites in United States
- Volunteers
- 108 people
- Sponsor
- Tris Pharma, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
While the Lisdexamfetamine Dimesylate (SPD489) clinical program has studied the efficacy, safety, and tolerability of SPD489 in treating core symptoms of ADHD in children and adolescents aged 6-17 years and adults aged 18-55…
- Trial name
- NCT01328756
- Testing
- Lisdexamfetamine dimesylate
- Where
- 35 sites in Belgium, Germany and 8 more
- Volunteers
- 314 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia
There has been an increased interest in the association between ADHD and sleep disorders over the past years. A high incidence of sleep disturbance, ranging from 10% to 70%, has been identified in ADHD children regardless of…
- Trial name
- Zolkids (NCT00318448)
- Testing
- Zolpidem (SL800750)
- Where
- 2 sites in United States, Canada
- Volunteers
- 201 people
- Sponsor
- Sanofi
ADHD, ADHD - Combined Type
Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.
The goal of this clinical trial is to evaluate the efficacy and safety of CTx-1301 in adults with ADHD in a laboratory classroom setting.
- Conditions
- ADHD, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention Deficit Hyperactivity Disorder
- Trial name
- NCT05631626
- Testing
- CTx-1301 - Dexmethylphenidate 25mg, CTx-1301 - Dexmethylphenidate 37.5mg, CTx-1301 - Dexmethylphenidate 50mg
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Cingulate Therapeutics
Attention Deficit Hyperactivity Disorder
A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder
The purpose of this study is to assess long-term safety and tolerability in adult patients who have completed a previous atomoxetine study.
- Trial name
- NCT00969618
- Testing
- Atomoxetine
- Where
- 12 sites in Japan
- Volunteers
- 211 people
- Sponsor
- Eli Lilly and Company
ADHD
A Randomized, Double-blind, Sham-controlled Pilot Study to Evaluate the Treatment Efficacy of Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) in College Students With ADHD
This pilot study is a randomized, double-blind, sham-controlled study designed to evaluate the efficacy of Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) in college students with ADHD. A total of 40 subjects will be treated.
- Trial name
- MeRT-USC-009 (NCT03066505)
- Testing
- Active MeRT Treatment
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Wave Neuroscience
Attention Deficit Hyperactivity Disorder, Dyslexia
Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia
This study will evaluate the effect of atomoxetine in treating Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children and adolescents with ADHD and comorbid reading disability (dyslexia)
- Trial name
- NCT00607919
- Testing
- Atomoxetine
- Where
- 16 sites in United States
- Volunteers
- 209 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder
The primary purpose of the study is to assess long-term safety and tolerability of Edivoxetine in pediatric participants with attention deficit hyperactive disorder (ADHD).
- Trial name
- NCT00965419
- Testing
- Edivoxetine
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 267 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity
A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of JNJ-31001074 in Pediatric Patients (12-17 Years) With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (process by which JNJ-31001074 is absorbed, distributed, metabolized, and eliminated by the body) after a single dose of JNJ-31001074.
- Trial name
- NCT00890292
- Testing
- JNJ-31001074
- Volunteers
- 18 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.